3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Emily Keeton of Loeb.nyc, Steve Kean of GHP, and Lacey Tezino of Passport Journeys. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from investing to mental health — recently making headlines in Houston innovation.

Emily Keeton, operating partner and investor of Loeb.nyc

Emily Keeton has worn a lot of hats in Houston's innovation ecosystem and beyond. She shares on the Houston Innovators Podcast how she's engaging with companies these days, what the future holds for Houston, and more. Photo courtesy

Emily Keeton has had a front-row seat as the Houston innovation ecosystem developed — first hands on as a co-founder of Station Houston, and later from outside looking in from New York. As she shared on the Houston Innovators Podcast, she's hopeful about the future of the community.

"I am very optimistic about the future of Houston. It's a long game, and I think people need to keep showing up," she says on the show.

Now based in Houston, her latest endeavor is working with Michael Loeb on Loeb.nyc, a New York-based investment firm with shared services — marketing, design, etc. — with his portfolio. Read more.

Steve Kean, incoming president and CEO of the Greater Houston Partnership

Steve Kean will transition from leading Kinder Morgan to assuming the role of president and CEO of the Greater Houston Partnership later this year. Photo courtesy of the GHP

Steve Kean, who currently serves as the CEO of Kinder Morgan Inc., has been announced as the next president and CEO of the Greater Houston Partnership. He's expected to transition from CEO to board of directors member at Kinder Morgan on August 1. Kean will then assume his new position at GHP no later than Dec. 1.

“I’m grateful for the opportunity to serve our region in this role," he says. "I look forward to building on what Bob, the Board, members, and staff of the Partnership have accomplished. I know first-hand the opportunities that a vibrant business sector can create for people and communities. I look forward to expanding those opportunities further.”

The GHP's outgoing president and CEO, Bob Harvey, announced his retirement earlier this year, and will remain in his position until Kean is onboarded. Read more.

A Houston-founded company is targeting mothers and daughters with their teletherapy app. Photo courtesy of Passport Journeys

When Lacey Tezino’s mother died of cancer she vowed to help other mothers and daughters find their own ways to bond in beautiful, nurturing ways. She turned that vow into a mission that is now available for others to embark on with an online therapy app tailored specifically for the mother-daughter dynamic Passport Journeys.

The app, which launched aptly on Mother's Day, can be downloaded via Apple or Google Play, and includes video therapy sessions, journal opportunities, interactive worksheets, and help those who need access to this form of mental health help with ease.

“Outside of our target audience being mother-daughter, we are also the first teletherapy app to find prescribed activities,“ Tezino tells InnovationMap. “We are the first ones that are actually having the therapist in between their video sessions assign the mother-daughter pair intentional bonding activities. It is meant for them to spend quality time on where they are at in their relationship…there aren’t any other apps that are doing that.” Read more.

From Your Site Articles

Long-time innovator shares why she's optimistic about Houston's future as a hub for startups, tech

HOUSTON INNOVATORS PODCAST EPISODE 191

As she describes, Emily Keeton's strength and her curse is that she lacks patience. For this reason, her career, launched originally in investment banking, has taken her from the startup world to media and beyond.

"I'm a person of action, and I think that works well when you work with a startup. You tend to get things done," Keeton says on the Houston Innovators Podcast, adding that she's been called a change agent, and while the terminology isn't her preference, she agrees its an accurate identifier for her. "I can step into a situation, and, after many years of working with so many different companies, I have a lens of pattern recognition of what's worked in the past and potential footfalls. It's what keeps me coming back to startups."

Keeton was one of the founding members of Station Houston — along with John "J.R." Reale, Grace Rodriguez, Blair Garrou, and some other innovators who played a central role in the organization almost a decade ago. The goal was to create a community where startup founders in Houston can go for support from mentors and peers. The organization rolled into into a few entities like the Ion and Capital Factory in 2018.

After her role at Station, Keeton's career took her back to New York, where she worked with WeWork, Mercado, Tempest, and other consumer-facing businesses. She always had one foot still in Houston, until she recently relocated to Houston entirely. She served as COO of Houston Landing, a new nonprofit journalism platform, and her latest endeavor is working with Michael Loeb on Loeb.nyc, a New York-based investment firm with shared services — marketing, design, etc. — with his portfolio.

"I'm based here, and I'll be doing a couple of things, working with a few of the portfolio companies," she says. "And I'm on the lookout for early stage companies here in Texas."

Keeton's perspective, having seen the Houston innovation ecosystem develop — first hands on in Houston, and later from outside looking in from New York — is hopeful. She says that with Station, they realized the power of mentorship — specifically of mentors who have led a startup through scale and exit. Now, Houston just needs more exits and success stories to grow that mentorship base.

"I am very optimistic about the future of Houston. It's a long game, and I think people need to keep showing up," she says on the show.

She adds that what's happening right now is a winter for startups, and she notes that this isn't just something seen in Houston. But this period of time can be an advantage to innovators.

"It's a great time to launch a company," Keeton says, explaining that a few years ago, checks were being written without significant due diligence. Now, this pace has slowed. "It provides a bit of breathing room for people to figure out their business model."

Keeton shares more on her observations of Houston's tech and startup scene and what she looks for in the startups she invests her time and money in on the show. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME